en
Scientific article
English

Clinical usefulness of therapeutic concentration monitoring for imatinib dosage individualization: results from a randomized controlled trial

Published inCancer chemotherapy and pharmacology, vol. 74, no. 6, p. 1307-1319
Publication date2014
Abstract

This study assessed whether a cycle of "routine" therapeutic drug monitoring (TDM) for imatinib dosage individualization, targeting an imatinib trough plasma concentration (C min) of 1,000 ng/ml (tolerance: 750-1,500 ng/ml), could improve clinical outcomes in chronic myelogenous leukemia (CML) patients, compared with TDM use only in case of problems ("rescue" TDM).

Keywords
  • Adult
  • Aged
  • Antineoplastic Agents/administration & dosage/pharmacokinetics/therapeutic use
  • Benzamides/administration & dosage/pharmacokinetics/therapeutic use
  • Dose-Response Relationship, Drug
  • Drug Monitoring/methods
  • Female
  • Follow-Up Studies
  • Humans
  • Individualized Medicine/methods
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive/drug therapy/pathology
  • Male
  • Middle Aged
  • Piperazines/administration & dosage/pharmacokinetics/therapeutic use
  • Prospective Studies
  • Pyrimidines/administration & dosage/pharmacokinetics/therapeutic use
  • Treatment Outcome
Citation (ISO format)
GOTTA, V et al. Clinical usefulness of therapeutic concentration monitoring for imatinib dosage individualization: results from a randomized controlled trial. In: Cancer chemotherapy and pharmacology, 2014, vol. 74, n° 6, p. 1307–1319. doi: 10.1007/s00280-014-2599-1
Main files (1)
Article (Published version)
accessLevelRestricted
Identifiers
ISSN of the journal0344-5704
428views
0downloads

Technical informations

Creation05/01/2015 12:48:00 PM
First validation05/01/2015 12:48:00 PM
Update time03/14/2023 11:15:12 PM
Status update03/14/2023 11:15:12 PM
Last indexation01/16/2024 5:55:16 PM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack